Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · November 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04294810). This is a study registration, not published results. Lead sponsor: Hoffmann-La Roche. Recruitment status: COMPLETED. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 620 participants (ACTUAL). Conditions: Non-Small Cell Lung Cancer. Interventions: DRUG: Atezolizumab; DRUG: Tiragolumab; DRUG: Matching Placebo. Primary outcome measures: Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS) , From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months); China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS , From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months); Global Cohort: Overall Survival (OS) in the PAS , From randomization to death from any cause (up to approximately 54.7 months); China Cohort: OS in the PAS , From randomization to death from any cause (up to approximately 49.1 months); Global Cohort: Number of Participants With Adverse Events (AEs) , Up to 65.1 months; China Cohort: Number of Participants With AEs , Up to 49.3 months; Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale , Up to 65.1 months; China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale , Up to 49.3 months. Brief summary: The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.